Claims

Defense Bar Commentary Highlights Practice Points for Biotech Securities Litigation

by

A panel of corporate advisors updated their 2017 survey of securities litigation involving development-stage biotech companies, providing important practice points for the institutional investor and concluding that biotech start-ups do not pose a greater securities class action risk compared to other companies. Stronger cases involved plaintiffs making credible allegations that defendants intentionally misrepresented data or facts about their interactions with the FDA, omitted adverse regulator feedback, or presented misleading information about regulatory milestones or assessments.

Temple Law Hosts Symposium: Contract in Crisis

by

Professor Jonathan Lipson and Interim Dean Rachel Rebouché hosted a workshop for contributions to Contract in Crisis, an upcoming special issue of Duke University’s LAW AND CONTEMPORARY PROBLEMS. Workshop topics included doctrinal solutions to addressing the concurrence of COVID-19 and income inequality, as well as the benefits of using private ordering solutions in times of public crisis in lieu of public regulation.